TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in ...
Both treatments were generally well tolerated, according to Regeneron. (Kong Ding Chek/iStock/Getty Images Plus) Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results